Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 6/20 | 0.79 |
| ▸ | DRD2 | P14416 | 5/20 | 0.79 |
| ▸ | DRD3 | P35462 | 4/20 | 0.79 |
| ▸ | HTR2C | P28335 | 6/20 | 0.53 |
| ▸ | HTR2B | P41595 | 4/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.45 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.45 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.45 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.45 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.45 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.45 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.45 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.45 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.44 |
| ▸ | MLNR | O43193 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21753256 | 0.98 | PNMT (0.76) | PNMTDRD2DRD3HTR2CHTR2B | |
| SCHEMBL1638541 | 0.88 | DRD2 (1.00) | PNMTDRD2DRD3 | |
| SCHEMBL29580085 | 0.88 | DRD2 (1.00) | PNMTDRD2DRD3 | |
| SCHEMBL351435 | 0.88 | PNMT (1.00) | PNMTDRD2DRD3 | |
| SCHEMBL29365632 | 0.88 | PNMT (1.00) | PNMTDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL4224148 | 0.86 | DRD2 (0.96) | PNMTDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL30015379 | 0.86 | DRD2 (0.96) | PNMTDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL65520 | 0.86 | PNMT (0.96) | PNMTDRD2DRD3 | |
| SCHEMBL5458702 | 0.85 | DRD2 (0.59) | PNMTDRD2DRD3HTR2CHTR2B | |
| SCHEMBL8222195 | 0.83 | PNMT (0.60) | PNMTDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114948963-B | Benzolactam compounds as protein kinase inhibitors | 大冢制药株式会社 | 2025-05-27 | — | — | CN | disclosed |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | RECOVERY THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | disclosed |
| EP-4291177-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | Recovery Therapeutics, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117157069-A | Compounds, compositions and methods for modulating FGF activity | 康复治疗公司 | 2023-12-01 | — | — | CN | disclosed |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2004037788-A1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
| EP-1335915-A2 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2003-08-20 | — | — | EP | disclosed |
| US-6605607-B1 | Antihypertensives; hyperprolactinaemia related conditions; certain central nervous system disorders | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-08-12 | — | — | US | disclosed |
| WO-2002040471-A9 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2003-07-31 | — | — | WO | disclosed |
| WO-2002040471-A2 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-23 | — | — | WO | disclosed |
| EP-1119563-A1 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021951-A1 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2000-04-20 | — | — | WO | disclosed |
| EP-0528369-B1 | Cyclic imino derivatives, pharmaceutical compositions containing them and process for their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 1999-11-24 | — | — | EP | disclosed |
| US-5455348-A | Anticoagulants | Thomae, Karl (DE) | 1995-10-03 | — | — | US | disclosed |
| EP-0528369-A2 | Cyclic imino derivatives, pharmaceutical compositions containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | PNMT 1178/4885DRD2 3577/4885DRD3 3340/4885 |
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | PNMT 3066/4885DRD2 3536/4885DRD3 3012/4885 |
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | FGF1, FGF2, FGFR1 | PNMT 4852/4885DRD2 4709/4885DRD3 4755/4885 |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | PNMT 1190/4885DRD2 3585/4885DRD3 3389/4885 |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | BACE1, BACE2, BCHE | PNMT 105/4885DRD2 1589/4885DRD3 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.